Moderna says its vaccine for ages under 6 will be ready for U.S. review
in June
Send a link to a friend
[May 02, 2022]
By Doina Chiacu
WASHINGTON (Reuters) - Moderna Inc's chief
medical officer said on Sunday the company's vaccine for children under
6 years old will be ready for review by a Food and Drug Administration
panel when it meets in June.
Moderna sought emergency use authorization from the FDA on Thursday.
An advisory panel of experts to the U.S. drug regulator will meet in
June to review the request.
"I think the FDA now have all of the core fundamental data they need to
be able to begin an application review. So yes, we're very confident,"
Dr. Paul Burton, the company's chief medical officer, said in an
interview with CBS' "Face the Nation."
Moderna's vaccine could be the first to win U.S. approval for children
under the age of 5. Pfizer Inc also expects to have its vaccine data for
children under 6 ready by the June review.
[to top of second column]
|
"The safety profile we've seen in
this vaccine in these very youngest kids is very reassuring - actual
rates of safety events even lower than we've seen in the 6-year-olds
to 12-year-olds and that's great," Burton said.
Moderna's vaccine is approved by the FDA for use in
adults 18 and older. But it has yet to be approved for 6- to
17-year-olds in the United States despite gaining approval for that
age group in Australia, Canada and the European Union. U.S.
regulators have asked the company for more safety data.
Burton said on Sunday the company is testing another booster shot
that he believes will be superior to booster results the company
announced on April 19. The booster shots target the Beta variant
plus the original coronavirus.
Moderna expects to have large amounts of a new booster vaccine by
this fall to protect against Omicron and other COVID-19 variants, he
said.
(Reporting by Doina Chiacu; Editing by Tim Ahmann and Lisa Shumaker)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |